Previous 10 | Next 10 |
home / stock / rgbpp / rgbpp news
Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic PR Newswire Initial Design and Testing Complete SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has previously discussed initiation...
Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic PR Newswire DuraCAR Drug Addresses Major Need in Solid Tumor Therapies SAN DIEGO , Nov. 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)ha...
Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space PR Newswire Understanding CAR-T Mechanism of Action SAN DIEGO , Oct. 26, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patent...
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy PR Newswire Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach SAN DIEGO , Se...
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy PR Newswire Company Engages Top-Tier Contract Research Organization SAN DIEGO , Sept. 13, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC P...
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors PR Newswire Company Develops A Two-Step Sequential Approach SAN DIEGO , Aug. 25, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PIN...
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors PR Newswire Company Creates "Younger T Cells" for Fighting Cancer Using its NR2F6 Technology SAN DIEGO , Aug. 11, 2022 /PR...
Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine PR Newswire Novel Means of Leveraging Cellular Therapy to "Teach" Immune System to Seek and Destroy Cancer SAN DIEGO , July 26, ...
Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio PR Newswire SAN DIEGO , March 16, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has an extensive intellectual property port...
Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies PR Newswire SAN DIEGO , March 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a progr...
News, Short Squeeze, Breakout and More Instantly...
Regen BioPharma Company Name:
RGBPP Stock Symbol:
OTCMKTS Market:
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC:RGBP) (OTC:RGBPP) The Company has announced that after interviewing several ca...
Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments PR Newswire SAN DIEGO , Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing sev...
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program PR Newswire SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic ( http...